Nantahala Capital Management LLC acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 809,914 shares of the company’s stock, valued at approximately $12,440,279.
A number of other hedge funds have also recently modified their holdings of JANX. BlackRock Inc. acquired a new stake in Janux Therapeutics during the second quarter worth about $94,228,000. Janus Henderson Group PLC raised its position in Janux Therapeutics by 13.8% during the fourth quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock valued at $73,850,000 after acquiring an additional 649,341 shares in the last quarter. State Street Corp raised its position in Janux Therapeutics by 103.8% during the fourth quarter. State Street Corp now owns 3,853,951 shares of the company’s stock valued at $53,185,000 after acquiring an additional 1,962,486 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock valued at $59,074,000 after acquiring an additional 227,676 shares during the period. Finally, Prosight Management LP lifted its holdings in Janux Therapeutics by 176.5% in the fourth quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock valued at $33,017,000 after acquiring an additional 1,527,173 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts have commented on JANX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Piper Sandler cut their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wedbush decreased their target price on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $35.00 price target on shares of Janux Therapeutics in a report on Friday, August 7th. Finally, Truist Financial restated a “buy” rating and set a $26.00 price target (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $36.46.
Janux Therapeutics Stock Down 4.0%
Shares of Janux Therapeutics stock opened at $18.03 on Friday. The firm has a market cap of $1.10 billion, a PE ratio of -10.99 and a beta of 2.50. Janux Therapeutics, Inc. has a twelve month low of $12.12 and a twelve month high of $35.34. The business has a 50-day moving average price of $16.12 and a 200 day moving average price of $14.81.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to the consensus estimate of $19.07 million. On average, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.76 EPS for the current year.
Insider Activity at Janux Therapeutics
In other news, insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This represents a 5.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by company insiders.
About Janux Therapeutics
Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.
Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.
Featured Stories
- Five stocks we like better than Janux Therapeutics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report).
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
